Latest research on Linezolid

Linezolid is a synthetic antibiotic, the first of the oxazolidinone class, used for the treatment of infections caused by multi-resistant bacteria including streptococcus and methicillin-resistant Staphylococcus aureus (MRSA). The drug works by inhibiting the initiation of bacterial protein synthesis.

Latest findings

According to the guideline recommendations, empiric intravenous (IV) Antimicrobial agents for the treatment of suspected severe MRSA ABSSSIs include Vancomycin, Daptomycin, Linezolid, telavancin, or Ceftaroline. [source, 2016]
Patients received either two doses of dalbavancin, 1 g initially followed by 500 mg on day 8 of treatment, or Vancomycin 1 g every 12 hours for ≥3 days, with the option of transitioning to oral Linezolid to Complete 10–14 days of therapy. [source, 2016]
Several in vitro models using either human or animal cells have been developed to study the activity of antibiotics against intracellular S. aureus, and a corresponding in vivo model (murine peritonitis) has recently been described and tested with antibiotics, including Linezolid, β-lactams, Gentamicin, Azithromycin, rifampicin, or dicloxacillin5650. [source, 2016]
We aim to develop an individualised optimal dosing algorithm that accounts for the relevant effects of RRT modalities and patient clinical characteristics on dosing requirements for Vancomycin, Linezolid, piperacillin-tazobactam and Meropenem. [source, 2016]
This is a multi-national observational PK study designed to analyse PK data using a population PK approach to identify covariates associated with changes in PK parameters for five commonly prescribed antibiotics, Vancomycin, Linezolid, piperacillin/tazobactam and Meropenem in critically ill patients with AKI who are undergoing RRT. [source, 2016]
Timely detection and targeted prevention of further dissemination of MRSA present on retail beef meat and the cfr gene becomes justified in order to preserve efficacy of Linezolid due to its importance and preference in the treatment of staphylococcal infections (Witte and Cuny, 2011). [source, 2016]
For Linezolid, at least 50 patients will be enrolled. [source, 2016]
Based on pre-study survey activities Linezolid is prescribed less frequently at the study sites. [source, 2016]
We will enrol at least 50 patients for Linezolid to allow for potential attrition. [source, 2016]
This comprehensive data set will permit the description of detailed PK data, and allow further analysis of the effect of critical illness, AKI and RRT on the drug disposition of five of the most commonly used antibiotics in ICU patients, namely, Vancomycin, Linezolid, piperacillin/tazobactam and Meropenem. [source, 2016]